Characterization of protein biomarkers in Alzheimer's disease and dementia with Lewy bodies
The OPTIMA cohort continues to be an invaluable resource for advancing diagnostic and treatment approaches in neurodegenerative diseases. In addition, given the substantial concentration differences of ATN-defining proteins in post-mortem ventricular samples than in lumbar CSF taken during life, this may limit the utility of post-mortem CSF as technical controls.
Authors
- Andrew M. Goldfine (ORCID: https://orcid.org/0000-0003-1962-5564)
- Aya Abdallah (ORCID: https://orcid.org/0000-0001-7594-5736)
- Laura Parkkinen (ORCID: https://orcid.org/0000-0002-3392-8564)
- Becky C. Carlyle (ORCID: https://orcid.org/0000-0003-1491-3217)
- Dominik Domański (ORCID: https://orcid.org/0000-0003-2549-1064)
- Robert Allen
- Sanjay Kumar
Institutions
- University of Oxford (GB)
- GlaxoSmithKline (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_098343
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00